GENinCode PLC Directorate Change (8040T)
29 November 2021 - 6:00PM
UK Regulatory
TIDMGENI
RNS Number : 8040T
GENinCode PLC
29 November 2021
29 November 2021
GENinCode Plc
("GENinCode" or the "Company")
Directorate change
GENinCode Plc (AIM: GENI), the predictive genetics company
focused on the prevention of cardiovascular disease, announces that
David Evans, Non-Executive Director, has notified the Board of his
intention to stand down from his role with immediate effect.
Bill Rhodes, Non-Executive Chairman of GENinCode Plc said: " We
would like to thank David for his invaluable contribution to
GENinCode during his tenure. David has worked with members of the
GENinCode management team for many years, and he has always
provided instrumental strategic advice and counsel from his wealth
of experience in the sector. On behalf of the Board, I would like
to wish him the very best for the future."
For further information please contact:
GENinCode Plc www.genincode.com or via Walbrook
PR
Matthew Walls, CEO
Paul Foulger, CFO
Stifel Nicolaus Europe Limited (Nomad Tel: +44 (0)20 7710 7600
and Joint Broker)
Alex Price / Ben Maddison / Richard Short
Cenkos Securities Plc (Joint Broker) Tel: +44 (0)20 7397 8900
Giles Balleny
Dale Bellis / Michael Johnson (Sales)
Walbrook PR Limited
Tel: 020 7933 8780 or genincode@walbrookpr.com
Anna Dunphy / Paul McManus / Louis Ashe-Jepson
About GENinCode plc
GENinCode plc is engaged in the risk assessment, prediction and
prevention of cardiovascular disease ("CVD"). CVD is the leading
cause of death worldwide accounting for approximately 18 million
deaths annually. The Company's products and technology have been
developed with the aim of predicting the onset of CVD and providing
a personalised treatment pathway for patient management. Its
products have been the subject of clinical studies on over 75,000
patients to assess and predict the onset of CVD.
The Company was incorporated in September 2018 to acquire the
assets, intellectual property and know-how of the Ferrer inCode and
Gendiag.exe businesses, which were then part of Grupo Ferrer
Internacional S.A., a large Spanish multinational private
pharmaceutical and healthcare company. The technology and products
acquired included Cardio inCode(R), Lipid inCode(R), Thrombo
inCode(R) and Sudd inCode(R). Approximately EUR50 million has been
invested in the research and development of these products since
2007. The Company has begun to commercialise these products in
Europe and is also targeting the UK and US.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAUWRORAVUAUUA
(END) Dow Jones Newswires
November 29, 2021 02:00 ET (07:00 GMT)
Genincode (LSE:GENI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genincode (LSE:GENI)
Historical Stock Chart
From Apr 2023 to Apr 2024